Investor
Crestline Management, LP
CIK 0001536054 · filed 2026-05-15 · SEC filing
13F book
$46.3M
Positions
3
Largest name
91.7%
Denali Therapeutics Inc. · DNLI
Est. mark
$4.74M
Price effect on 3 names still held. Flow −$11.8M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Denali Therapeutics Inc. | DNLI | 2.21M | $42.4M | 91.7% | $5.95M | Cut−$3.96M |
| Sana Biotechnology, Inc. | SANA | 755.7K | $2.18M | 4.7% | −$899.3K | Cut−$2.79M |
| 8x8 Inc New | — | 990.9K | $1.64M | 3.6% | −$307.6K | Added−$307.2K |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.